ESR1 and breast neoplasm: Our two‐gene (GATA3 and AGR3) IHC‐based panel could classify the histologic grade III ER+HER2− breast tumors into luminal‐like and non‐luminal‐like subtypes, for whom the benefit from endocrine therapy is limited.